Oruka Therapeutics Inc
Company Profile
Business description
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Contact
855 Oak Grove Avenue
Suite 100
Menlo ParkCA94025
USAT: +1 650 606-7910
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
28
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,421.70 | 21.90 | 0.26% |
| CAC 40 | 7,705.17 | 78.33 | 1.03% |
| DAX 40 | 23,396.52 | 280.56 | 1.21% |
| Dow JONES (US) | 41,113.97 | 284.97 | 0.70% |
| FTSE 100 | 8,593.80 | 34.47 | 0.40% |
| HKSE | 22,775.92 | 84.04 | 0.37% |
| NASDAQ | 17,738.16 | 48.50 | 0.27% |
| Nikkei 225 | 36,928.63 | 148.97 | 0.41% |
| NZX 50 Index | 12,467.03 | 29.86 | -0.24% |
| S&P 500 | 5,631.28 | 24.37 | 0.43% |
| S&P/ASX 200 | 8,191.70 | 13.40 | 0.16% |
| SSE Composite Index | 3,352.00 | 9.33 | 0.28% |